Details For Selected Brain Tumor Treatment

Sponsored By

Cedars-Siani Medical Center Brain Tumor Program

Please Click On The Above Banner For More Details

Back to New Treatments List


		Treatment Name:		Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

		Phase:		Phase 1

		Treatment ID#:		1598 NCT00049023

		Age Group:		Adult And Pediatric

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Histologically or cytologically confirmed malignant neoplasm Not amenable to standard therapy or has failed existing first- and second-line therapies Tumor positive for somatostatin receptors by OctreoScan within the past 4 weeks At least 1 measurable lesion Lesions that have been previously irradiated must demonstrate progression since radiation At least 1 measurable somatostatin receptor-positive lesion that has not been irradiated within the past 4 weeks AND has not had full craniospinal radiation within the past 3 months

		Last Updated:		11/06/2005

		Tumor Types:		Any Malignant Brain Tumor Glioblastoma Multiforme Gliosarcoma Recurrent Malignant Pediatric Brain Tumors


		Comments:		RATIONALE: Radiolabeled octreotide can locate tumor cells and deliver radioactive tumor-killing substances to them without harming normal cells. PURPOSE: This phase I trial is studying the effectiveness of radiolabeled octreotide in treating children who have advanced or refractory solid tumors.

		Treatment Type:		Immunological, Biological or Targeted Therapy

		Contact:		M. Sue O`Dorisio MD, PhD Holden Comprehensive Cancer Center at University of Iowa Iowa City, IA 52242-1009 USA Phone: 319-356-7873 Fax: E-mail: sue_odorisio@uiowa.edu Website:

Last updated refers to the date when our listing for each treatment was last updated.
ID is a combination of our internal ID and the official ID for the trial, if any.
Min Karnofsky is a general guide to how well you have to function to use this treatment

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By